ACUTE TRANSVERSE MYELOPATHY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL PRESENTATION, TREATMENT, AND OUTCOME

Citation
Cc. Mok et al., ACUTE TRANSVERSE MYELOPATHY IN SYSTEMIC LUPUS-ERYTHEMATOSUS - CLINICAL PRESENTATION, TREATMENT, AND OUTCOME, Journal of rheumatology, 25(3), 1998, pp. 467-473
Citations number
17
Categorie Soggetti
Rheumatology
Journal title
ISSN journal
0315162X
Volume
25
Issue
3
Year of publication
1998
Pages
467 - 473
Database
ISI
SICI code
0315-162X(1998)25:3<467:ATMISL>2.0.ZU;2-V
Abstract
Objective. Acute transverse myelopathy (ATM) is a rare manifestation o f systemic lupus erythematosus (SLE). The pathogenesis is unclear and the optimal management strategy is uncertain because of the lack of co ntrolled trials. In this study, the clinical presentation, autoantibod y profile, treatment, and outcome of cases of ATM in our local SLE pop ulation were retrospectively analyzed and compared with SLE controls. Results. Ten cases of ATM were identified among 315 patients with SLE studied, giving a prevalence of 3.2%. In 5 of the patients, ATM was th e initial manifestation of SLE. The cervical cord was the most common site of involvement (50%). Cerebrospinal fluid abnormalities were pres ent in 63% of the patients, while magnetic resonance imaging (MRI) of the spinal cord revealed abnormal T2 signals in 56%. Only one patient had lupus nephritis. ATM was not associated with antiribosomal P or an ti-extractable nuclear antigen (anti-ENA) antibodies. Positive dsDNA a ntibody was present in 40% of the ATM cases, which was significantly l ower than that of patients with active SLE without spinal cord disease (75%; p = 0.04). No significant differences in the prevalence of anti cardiolipin antibodies and lupus anticoagulant between the ATM and the non-ATM group were observed. Only 3 patients with ATM showed hypocomp lementemia or disease activity in other organs at the time of diagnosi s, All the patients with ATM received corticosteroids, while 9 were gi ven cytotoxic agents in addition. The response to treatment was variab le -40% of patients had complete motor and sphincter recovery and 30% had mild residual spasticity of the lower limbs. Conclusion. In our SL E population, ATM was not associated with antiribosomal P, anti-ENA, o r antiphospholipid antibodies. Systemic complement activation was not evident in most patients during the acute phase of myelitis. Early agg ressive therapy using a combination of corticosteroid and cytotoxic ag ents is associated with a satisfactory outcome. Further prospective st udy is needed to delineate the best treatment and its efficacy in the prevention of relapses.